查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2111191

晶片器官（OoC）市場：預測至2034年－全球分析（按產品類型、器官類型、材料、細胞來源、製造方法、產能、工作流程階段、疾病領域、技術、應用、最終用戶和地區分類）

Organ-on-a-Chip Market Forecasts To 2034 - Global Analysis By Product, Organ Type, Material, Cell Source, Fabrication Method, Throughput, Workflow Stage, Disease Area, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球晶片器官 (OoC) 市場規模將達到 2.816 億美元，在預測期內以 33.8% 的複合年成長率成長，到 2034 年將達到 28.926 億美元。

晶片器官（Organ-on-a-Chip，OoC）是指利用微流體裝置中的活細胞來模擬人體器官的生物學行為和功能特徵的先進微工程平台。透過複製關鍵的生理條件，例如體液循環、機械刺激和細胞間通訊，這些系統為研究人類健康和疾病提供了逼真的模型。由於與傳統的實驗室模型相比，它們具有更高的預測準確性，因此被廣泛應用於藥物研發、安全性評估、精準醫療和生物醫學研究。組織工程、微加工技術和細胞生物學的不斷進步正在擴展其應用範圍，加速療法的開發，並減少對傳統動物實驗方法的依賴。

增加對精準醫療和疾病建模的投資

精準醫療投入的增加正在加速器官晶片（OoC）平台在醫學研究的應用。透過整合患者特異性細胞，這些技術能夠建構個人化的組織模型，忠實地模擬個別生物反應。研究人員可以在模擬人體生理功能的條件下評估治療效果和疾病進展，從而改善治療方案的發展。來自政府、醫療機構和製藥公司的資金投入不斷增加，推動了這些系統的廣泛應用。它們在癌症、心血管疾病和神經系統疾病等複雜疾病研究中的有效性，使其在推動個人化醫療和支持創新生物醫學研究舉措的重要性日益凸顯。

高昂的開發和實施成本

晶片器官（OoC）技術所需的大量資金持續限制其在市場上的廣泛應用。製造高精度微流體控裝置需要昂貴的材料、精密的製造技術和經驗豐富的專業人員，增加了整體生產成本。此外，在將這些平台整合到研究流程中之前，各機構必須投入資源用於專用設備、營運支援和人力資源開發。預算限制常常阻礙小規模生技公司、大學和研究中心投資這項技術。這些經濟挑戰限制了技術的普及，減緩了商業性擴張，並阻礙了其廣泛應用，尤其是在科學基礎設施和研究經費相對有限的地區。

化妝品和化學物質安全測試的開發

晶片器官（OoC）技術在化妝品和化學產品評估領域的應用日益廣泛，為OoC產業帶來了巨大的發展機會。隨著法規越來越鼓勵採用動物試驗的替代方案，製造商正積極採用先進的人體細胞平台進行安全性和毒性評估。 OoC設備能夠精確模擬皮膚、肝臟和肺部等組織的反應，為成分評估提供可靠的數據。消費者對符合倫理規範的產品的日益偏好以及更嚴格的安全要求，正在推動對這些技術的投資。預計OoC技術在醫藥研究之外的更廣泛應用，將創造新的收入來源，並促進多個行業領域的長期市場成長。

經濟不確定性及科學研究經費限制

景氣衰退和科學研究經費削減對晶片器官（OoC）市場的持續擴張構成重大風險。政府、大學和生命科學公司的預算限制可能迫使這些機構推遲對尖端實驗室技術的投資。由於晶片器官平台通常需要專門的基礎設施和訓練有素的人員，財務壓力會顯著影響其應用決策。資金籌措機會的減少也可能導致研究合作、產品創新和商業化活動萎縮。如果經濟不確定性持續存在，市場參與企業可能會面臨收入成長放緩和在全球生物醫學研究領域拓展業務的機會減少。

新型冠狀病毒（COVID-19）的影響：

新冠疫情凸顯了對更精準的人體研究平台的需求，加速了晶片器官（OoC）技術的應用。科學家利用這些系統闡明了新冠病毒的傳播途徑，評估了潛在的治療方法，並在真實的生物環境中檢驗了免疫系統的反應。生命科學、生物醫學研究和微流體技術資金的增加進一步推動了創新和商業化發展。儘管這些優勢顯而易見，但市場也面臨一些短期挑戰，包括組件供應中斷、實驗室暫時關閉以及與新冠疫情無關的研究活動延誤。疫情後，人們對這項技術的認知度持續提升，推動了投資和市場的長期擴張。

在預測期內，晶片器官（OoC）設備細分市場預計將佔據最大的市場佔有率。

預計在預測期內，器官晶片（OoC）設備將佔據最大的市場佔有率，這主要得益於此類設備在藥物研發、疾病建模和毒性測試中模擬人體器官功能方面發揮的核心作用。微流體、生物材料和晶片製造技術的不斷進步正在提升其生理精確度和研究能力。製藥公司、生物技術公司和學術機構正擴大採用先進的器官晶片設備，以提高臨床前試驗的效率並減少對傳統實驗室模型的依賴。精準醫療和生物醫學研究領域應用範圍的不斷擴大，進一步鞏固了其長期市場需求。

在預測期內，混合材料領域預計將呈現最高的複合年成長率。

在預測期內，混合材料領域預計將呈現最高的成長率，這主要得益於對晶片器官（OoC）平台日益成長的需求。這類平台結合了多種材料的優勢，能夠實現卓越的生物性能、微流體穩定性和微流控功能。混合材料能夠改善細胞黏附、增強生物相容性並提高裝置設計的柔軟性，使其適用於複雜的器官建模應用。研究人員和製造商正擴大利用這些材料開發能夠模擬複雜生理環境的新一代晶片。材料科學和組織工程領域的持續創新有望進一步加速這些材料在生物醫學和製藥研究領域的應用。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這得益於其先進的醫療保健基礎設施、製藥和生物技術公司的集中佈局以及對生命科學研究的大量投資。此外，該地區學術機構、研究實驗室和技術提供者之間的積極合作正在推動晶片器官（OoC）應用領域的持續創新。對以人為中心的檢測模型的日益重視、不斷成長的研究經費以及精準醫療和藥物發現的持續進展，都有助於北美保持市場領先地位，鞏固其在區域市場的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。在該地區，生物技術、製藥製造和生物醫學研究正迅速發展，這得益於政府和私人機構投資的增加。由於醫療基礎設施的改善、研究合作的加強以及臨床研究活動的擴展，晶片器官技術的應用正在加速。中國、日本、韓國和印度等國家正在加強其在微流體、組織工程和精準醫療方面的能力。對創新藥物發現平台和以人為本的檢測方法日益成長的需求預計將進一步推動該地區的市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球晶片器官（OoC）市場：依產品分類

  • 晶片器官裝置
  • 裝置
  • 消耗品
  • 軟體

第6章 全球晶片器官（OoC）市場：依器官類型分類

  • Liver-on-a-Chip
  • Lung-on-Chip
  • Heart-on-Chip
  • Kidney-on-a-Chip
  • Gut-on-Chip
  • Brain-on-a-Chip
  • Skin-on-Chip
  • Blood Vessel-on-Chip
  • Bone Marrow-on-Chip
  • Pancreas-on-Chip
  • Placenta-on-Chip
  • Retina-on-a-Chip
  • Tumor-on-a-Chip
  • Lymph Node-on-Chip
  • Multi-Organ-on-Chip

第7章 全球晶片器官（OoC）市場：依材料分類

  • 聚二甲基矽氧烷
  • 熱塑性塑膠
  • 玻璃
  • 矽
  • 水凝膠
  • 基於細胞外基質的材料
  • 混合材料

第8章 全球晶片器官（OoC）市場：依細胞來源分類

  • 原代培養細胞
  • 誘導性多功能幹細胞
  • 胚胎幹細胞
  • 永生化細胞株
  • 患者來源細胞

第9章 全球晶片器官（OoC）市場：依製造方法分類

  • 軟光刻
  • 射出成型
  • 3D列印
  • 銑床
  • 雷射微加工
  • 熱壓印法

第10章 全球晶片器官（OoC）市場：依吞吐量分類

  • 低通量平台
  • 中等通量平台
  • 高通量平台

第11章 全球晶片器官（OoC）市場：依工作流程階段分類

  • 藥物發現的早期階段
  • 臨床前研究
  • 轉化研究
  • 安全性和毒性評估
  • 精準醫療調查

第12章 全球晶片器官（OoC）市場：依疾病領域分類

  • 腫瘤學
  • 心血管疾病
  • 神經病變
  • 呼吸系統疾病
  • 感染疾病
  • 消化系統疾病
  • 代謝性疾病
  • 腎臟疾病
  • 肝病
  • 罕見疾病
  • 自體免疫疾病

第13章 全球晶片器官（OoC）市場：依技術分類

  • 微流體技術
  • 3D細胞培養
  • 組織工程
  • 3D生物列印
  • 幹細胞技術
  • 生物感測器整合
  • Organoid-on-Chip

第14章 全球晶片器官（OoC）市場：依應用分類

  • 藥物發現
  • 藥物篩檢
  • 毒性測試
  • 疾病建模
  • 個人化醫療
  • ADME 研究
  • 藥物動力學（PK）研究
  • 動態（PD）研究
  • 癌症研究
  • 再生醫學研究
  • 感染疾病研究
  • 神經科學研究
  • 化妝品測試

第15章 全球晶片器官（OoC）市場：依最終用戶分類

  • 製藥公司
  • 生技公司
  • 受託研究機構（CRO）
  • 學術研究機構
  • 醫院和臨床研究中心
  • 監管機構

第16章 全球晶片器官（OoC）市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第17章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第18章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第19章：公司簡介

  • Emulate, Inc.
  • MIMETAS BV
  • CN Bio Innovations Ltd.
  • TissUse GmbH
  • Nortis Inc.
  • InSphero AG
  • AlveoliX AG
  • Cherry Biotech SAS
  • AxoSim, Inc.
  • Hesperos, Inc.
  • Dynamic42 GmbH
  • BEOnChip SL
  • Kirkstall Ltd.
  • Bi/ond Solutions BV
  • NETRI
  • AIM Biotech Pte. Ltd.
  • BiomimX Srl
  • React4Life SpA
Product Code: SMRC38890

According to Stratistics MRC, the Global Organ-on-a-Chip Market is accounted for $281.6 million in 2026 and is expected to reach $2892.6 million by 2034 growing at a CAGR of 33.8% during the forecast period. Organ-on-a-Chip refers to an advanced microengineered platform that mimics the biological behavior and functional characteristics of human organs using living cells within micro fluidic devices. By reproducing key physiological conditions such as fluid circulation, mechanical stimulation, and cell-to-cell communication, these systems provide realistic models for studying human health and disease. They are widely adopted in pharmaceutical research, safety assessment, precision medicine, and biomedical investigations to improve predictive accuracy compared with traditional laboratory models. Continuous progress in tissue engineering, microfabrication, and cell biology is expanding their capabilities, supporting faster therapeutic development and reducing dependence on conventional animal-based testing methods.

Market Dynamics:

Driver:

Increasing Investment in Precision Medicine and Disease Modelling

Growing investment in precision medicine is accelerating the adoption of Organ-on-a-Chip platforms across healthcare research. By incorporating patient-specific cells, these technologies create personalized tissue models that closely represent individual biological responses. Researchers can assess therapeutic effectiveness and disease progression under conditions that mimic human physiology, improving treatment development strategies. Increased funding from governments, medical institutions, and pharmaceutical companies is encouraging broader implementation of these systems. Their effectiveness in studying complex disorders such as cancer, cardiovascular diseases, and neurological conditions enhances their importance in advancing personalized therapies and supporting innovative biomedical research initiatives.

Restraint:

High Development and Implementation Costs

Significant financial requirements associated with Organ-on-a-Chip technology continue to restrict broader market adoption. Manufacturing highly engineered microfluidic devices involves expensive materials, precision fabrication techniques, and experienced professionals, increasing overall production costs. Organizations must also allocate resources for specialized instruments, operational support, and workforce training before integrating these platforms into research workflows. Budget limitations frequently prevent smaller biotechnology firms, universities, and research centers from investing in the technology. These economic challenges reduce accessibility, slow commercial expansion, and hinder widespread deployment, particularly in regions where scientific infrastructure and research funding remain relatively limited.

Opportunity:

Expansion into Cosmetic and Chemical Safety Testing

Expanding applications in cosmetic and chemical product evaluation present significant opportunities for the Organ-on-a-Chip industry. As regulations increasingly encourage alternatives to animal-based testing, manufacturers are adopting advanced human-cell platforms for safety and toxicity assessments. Organ-on-a-Chip devices can accurately simulate the responses of tissues such as skin, liver, and lungs, providing reliable data for ingredient evaluation. Rising consumer preference for ethically developed products and stricter safety requirements are driving investment in these technologies. Their growing acceptance beyond pharmaceutical research is expected to create new revenue streams and strengthen long-term market growth across multiple industrial sectors.

Threat:

Economic Uncertainty and Research Funding Constraints

Economic downturns and reduced research funding pose considerable risks to the continued expansion of the Organ-on-a-Chip market. Budget constraints within governments, universities, and life science companies may lead organizations to postpone investments in advanced laboratory technologies. Because Organ-on-a-Chip platforms often require specialized infrastructure and trained personnel, financial pressures can significantly influence adoption decisions. Lower funding availability may also reduce research collaborations, product innovation, and commercialization activities. If economic uncertainty persists, market participants could experience slower revenue growth and fewer opportunities to expand their presence across global biomedical research sectors.

Covid-19 Impact:

The COVID-19 outbreak accelerated the adoption of Organ-on-a-Chip technology by highlighting the need for more accurate human-based research platforms. Scientists used these systems to study coronavirus infection pathways, assess potential treatments, and examine immune system responses in realistic biological environments. Increased funding for life sciences, biomedical research, and microfluidic technologies further supported innovation and commercial development. Despite these advantages, the market experienced short-term challenges, including disruptions in component supply, temporary laboratory closures, and postponed research activities unrelated to COVID-19. Following the pandemic, broader recognition of the technology has continued to drive investment and long-term market expansion.

The Organ-on-Chip Devices segment is expected to be the largest during the forecast period

The Organ-on-Chip Devices segment is expected to account for the largest market share during the forecast period, driven by the central role these devices play in replicating human organ functions for drug discovery, disease modeling, and toxicity testing. Continuous advancements in microfluidic engineering, biomaterials, and chip fabrication have improved their physiological accuracy and research capabilities. Pharmaceutical companies, biotechnology firms, and academic institutions are increasingly adopting advanced Organ-on-Chip devices to enhance preclinical testing efficiency and reduce dependence on conventional laboratory models. Their expanding application across precision medicine and biomedical research further strengthens long-term market demand.

The Hybrid Materials segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Hybrid Materials segment is predicted to witness the highest growth rate, driven by the increasing need for Organ-on-a-Chip platforms that combine the advantages of multiple materials to achieve superior biological performance, mechanical stability, and microfluidic functionality. Hybrid materials enable improved cell adhesion, enhanced biocompatibility, and greater flexibility in device design, making them suitable for complex organ modeling applications. Researchers and manufacturers are increasingly utilizing these materials to develop next-generation chips capable of simulating intricate physiological environments. Continuous innovation in material science and tissue engineering is expected to further accelerate adoption across biomedical and pharmaceutical research.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare infrastructure, a strong concentration of pharmaceutical and biotechnology companies, and significant investment in life science research. The region also benefits from active partnerships between academic institutions, research laboratories, and technology providers, fostering continuous innovation in Organ-on-a-Chip applications. Growing emphasis on human-relevant testing models, increasing research funding, and ongoing developments in precision medicine and drug development contribute to sustained market leadership, strengthening North America's position as the leading regional market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, The region is experiencing rapid expansion in biotechnology, pharmaceutical manufacturing, and biomedical research, supported by increasing investments from both governments and private organizations. Growing healthcare infrastructure, rising research collaborations, and expanding clinical research activities are accelerating the adoption of Organ-on-a-Chip technologies. Countries such as China, Japan, South Korea, and India are strengthening their capabilities in microfluidics, tissue engineering, and precision medicine. Increasing demand for innovative drug development platforms and human-relevant testing methods is expected to further fuel regional market growth.

Key players in the market

Some of the key players in Organ-on-a-Chip Market include Emulate, Inc., MIMETAS B.V., CN Bio Innovations Ltd., TissUse GmbH, Nortis Inc., InSphero AG, AlveoliX AG, Cherry Biotech SAS, AxoSim, Inc., Hesperos, Inc., Dynamic42 GmbH, BEOnChip S.L., Kirkstall Ltd., Bi/ond Solutions B.V., NETRI, AIM Biotech Pte. Ltd., BiomimX S.r.l. and React4Life S.p.A.

Key Developments:

In May 2026, Bio Innovations Ltd. Joined the Critical Path Institute (C-Path) New Approach Methodologies Developers Coalition (NAMs-DC) as a collaborative member to advance regulatory adoption of new approach methodologies, including Organ-on-a-Chip platforms, for drug development.

In April 2026, Dynamic42 GmbH entered a strategic collaboration with EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH to integrate Organ-on-a-Chip technology into preclinical glioblastoma research.

In February 2026, InSphero AG Formed a strategic partnership with PharmaNest Inc. to combine InSphero's human-relevant 3D liver models with AI-enabled digital pathology for improved translational fibrosis research and therapeutic evaluation.

Products Covered:

  • Organ-on-Chip Devices
  • Instruments
  • Consumables
  • Software

Organ Types Covered:

  • Liver-on-Chip
  • Lung-on-Chip
  • Heart-on-Chip
  • Kidney-on-Chip
  • Gut-on-Chip
  • Brain-on-Chip
  • Skin-on-Chip
  • Blood Vessel-on-Chip
  • Bone Marrow-on-Chip
  • Pancreas-on-Chip
  • Placenta-on-Chip
  • Retina-on-Chip
  • Tumor-on-Chip
  • Lymph Node-on-Chip
  • Multi-Organ-on-Chip

Materials Covered:

  • Polydimethylsiloxane
  • Thermoplastics
  • Glass
  • Silicon
  • Hydrogels
  • Extracellular Matrix-Based Materials
  • Hybrid Materials

Cell Sources Covered:

  • Primary Cells
  • Induced Pluripotent Stem Cells
  • Embryonic Stem Cells
  • Immortalized Cell Lines
  • Patient-Derived Cells

Fabrication Methods Covered:

  • Soft Lithography
  • Injection Moulding
  • 3D Printing
  • Micro-Milling
  • Laser Micromachining
  • Hot Embossing

Throughputs Covered:

  • Low-Throughput Platforms
  • Medium-Throughput Platforms
  • High-Throughput Platforms

Workflow Stages Covered:

  • Early Drug Discovery
  • Preclinical Research
  • Translational Research
  • Safety & Toxicology Assessment
  • Precision Medicine Research

Disease Areas Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Respiratory Diseases
  • Infectious Diseases
  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Renal Diseases
  • Hepatic Diseases
  • Rare Diseases
  • Autoimmune Diseases

Technologies Covered:

  • Micro fluidics
  • 3D Cell Culture
  • Tissue Engineering
  • 3D Bio printing
  • Stem Cell Technology
  • Biosensor Integration
  • Organoid-on-Chip

Applications Covered:

  • Drug Discovery
  • Drug Screening
  • Toxicity Testing
  • Disease Modeling
  • Personalized Medicine
  • ADME Studies
  • Pharmacokinetic (PK) Studies
  • Pharmacodynamic (PD) Studies
  • Cancer Research
  • Regenerative Medicine Research
  • Infectious Disease Research
  • Neuroscience Research
  • Cosmetic Testing

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Hospitals & Clinical Research Centers
  • Regulatory Agencies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Organ-on-a-Chip Market, By Product

  • 5.1 Organs-on-Chip Devices
  • 5.2 Instruments
  • 5.3 Consumables
  • 5.4 Software

6 Global Organ-on-a-Chip Market, By Organ Type

  • 6.1 Liver-on-Chip
  • 6.2 Lung-on-Chip
  • 6.3 Heart-on-Chip
  • 6.4 Kidney-on-Chip
  • 6.5 Gut-on-Chip
  • 6.6 Brain-on-Chip
  • 6.7 Skin-on-Chip
  • 6.8 Blood Vessel-on-Chip
  • 6.9 Bone Marrow-on-Chip
  • 6.10 Pancreas-on-Chip
  • 6.11 Placenta-on-Chip
  • 6.12 Retina-on-Chip
  • 6.13 Tumor-on-Chip
  • 6.14 Lymph Node-on-Chip
  • 6.15 Multi-Organ-on-Chip

7 Global Organ-on-a-Chip Market, By Material

  • 7.1 Polydimethylsiloxane
  • 7.2 Thermoplastics
  • 7.3 Glass
  • 7.4 Silicon
  • 7.5 Hydrogels
  • 7.6 Extracellular Matrix-Based Materials
  • 7.7 Hybrid Materials

8 Global Organ-on-a-Chip Market, By Cell Source

  • 8.1 Primary Cells
  • 8.2 Induced Pluripotent Stem Cells
  • 8.3 Embryonic Stem Cells
  • 8.4 Immortalized Cell Lines
  • 8.5 Patient-Derived Cells

9 Global Organ-on-a-Chip Market, By Fabrication Method

  • 9.1 Soft Lithography
  • 9.2 Injection Molding
  • 9.3 3D Printing
  • 9.4 Micro-Milling
  • 9.5 Laser Micromachining
  • 9.6 Hot Embossing

10 Global Organ-on-a-Chip Market, By Throughput

  • 10.1 Low-Throughput Platforms
  • 10.2 Medium-Throughput Platforms
  • 10.3 High-Throughput Platforms

11 Global Organ-on-a-Chip Market, By Workflow Stage

  • 11.1 Early Drug Discovery
  • 11.2 Preclinical Research
  • 11.3 Translational Research
  • 11.4 Safety & Toxicology Assessment
  • 11.5 Precision Medicine Research

12 Global Organ-on-a-Chip Market, By Disease Area

  • 12.1 Oncology
  • 12.2 Cardiovascular Diseases
  • 12.3 Neurological Disorders
  • 12.4 Respiratory Diseases
  • 12.5 Infectious Diseases
  • 12.6 Gastrointestinal Disorders
  • 12.7 Metabolic Disorders
  • 12.8 Renal Diseases
  • 12.9 Hepatic Diseases
  • 12.10 Rare Diseases
  • 12.11 Autoimmune Diseases

13 Global Organ-on-a-Chip Market, By Technology

  • 13.1 Microfluidics
  • 13.2 3D Cell Culture
  • 13.3 Tissue Engineering
  • 13.4 3D Bio printing
  • 13.5 Stem Cell Technology
  • 13.6 Biosensor Integration
  • 13.7 Organoid-on-Chip

14 Global Organ-on-a-Chip Market, By Application

  • 14.1 Drug Discovery
  • 14.2 Drug Screening
  • 14.3 Toxicity Testing
  • 14.4 Disease Modelling
  • 14.5 Personalized Medicine
  • 14.6 ADME Studies
  • 14.7 Pharmacokinetic (PK) Studies
  • 14.8 Pharmacodynamic (PD) Studies
  • 14.9 Cancer Research
  • 14.10 Regenerative Medicine Research
  • 14.11 Infectious Disease Research
  • 14.12 Neuroscience Research
  • 14.13 Cosmetic Testing

15 Global Organ-on-a-Chip Market, By End User

  • 15.1 Pharmaceutical Companies
  • 15.2 Biotechnology Companies
  • 15.3 Contract Research Organizations (CROs)
  • 15.4 Academic & Research Institutes
  • 15.5 Hospitals & Clinical Research Centers
  • 15.6 Regulatory Agencies

16 Global Organ-on-a-Chip Market, By Geography

  • 16.1 North America
    • 16.1.1 United States
    • 16.1.2 Canada
    • 16.1.3 Mexico
    • 16.2.1 Europe
    • 16.2.1 United Kingdom
    • 16.2.2 Germany
    • 16.2.3 France
    • 16.2.4 Italy
    • 16.2.5 Spain
    • 16.2.6 Netherlands
    • 16.2.7 Belgium
    • 16.2.8 Sweden
    • 16.2.9 Switzerland
    • 16.2.10 Poland
    • 16.2.11 Rest of Europe
  • 16.3 Asia Pacific
    • 16.3.1 China
    • 16.3.2 Japan
    • 16.3.3 India
    • 16.3.4 South Korea
    • 16.3.5 Australia
    • 16.3.6 Indonesia
    • 16.3.7 Thailand
    • 16.3.8 Malaysia
    • 16.3.9 Singapore
    • 16.3.10 Vietnam
    • 16.3.11 Rest of Asia Pacific
  • 16.4 South America
    • 16.4.1 Brazil
    • 16.4.2 Argentina
    • 16.4.3 Colombia
    • 16.4.4 Chile
    • 16.4.5 Peru
    • 16.4.6 Rest of South America
  • 16.5 Rest of the World (RoW)
    • 16.5.1 Middle East
      • 16.5.1.1 Saudi Arabia
      • 16.5.1.2 United Arab Emirates
      • 16.5.1.3 Qatar
      • 16.5.1.4 Israel
      • 16.5.1.5 Rest of Middle East
    • 16.5.2 Africa
      • 16.5.2.1 South Africa
      • 16.5.2.2 Egypt
      • 16.5.2.3 Morocco
      • 16.5.2.4 Rest of Africa

17 Strategic Market Intelligence

  • 17.1 Industry Value Network and Supply Chain Assessment
  • 17.2 White-Space and Opportunity Mapping
  • 17.3 Product Evolution and Market Life Cycle Analysis
  • 17.4 Channel, Distributor, and Go-to-Market Assessment

18 Industry Developments and Strategic Initiatives

  • 18.1 Mergers and Acquisitions
  • 18.2 Partnerships, Alliances, and Joint Ventures
  • 18.3 New Product Launches and Certifications
  • 18.4 Capacity Expansion and Investments
  • 18.5 Other Strategic Initiatives

19 Company Profiles

  • 19.1 Emulate, Inc.
  • 19.2 MIMETAS B.V.
  • 19.3 CN Bio Innovations Ltd.
  • 19.4 TissUse GmbH
  • 19.5 Nortis Inc.
  • 19.6 InSphero AG
  • 19.7 AlveoliX AG
  • 19.8 Cherry Biotech SAS
  • 19.9 AxoSim, Inc.
  • 19.10 Hesperos, Inc.
  • 19.11 Dynamic42 GmbH
  • 19.12 BEOnChip S.L.
  • 19.13 Kirkstall Ltd.
  • 19.14 Bi/ond Solutions B.V.
  • 19.15 NETRI
  • 19.16 AIM Biotech Pte. Ltd.
  • 19.17 BiomimX S.r.l.
  • 19.18 React4Life S.p.A.

List of Tables

  • Table 1 Global Organ-on-a-Chip Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Organ-on-a-Chip Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Organ-on-a-Chip Market Outlook, By Organ-on-Chip Devices (2023-2034) ($MN)
  • Table 4 Global Organ-on-a-Chip Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 5 Global Organ-on-a-Chip Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 6 Global Organ-on-a-Chip Market Outlook, By Software (2023-2034) ($MN)
  • Table 7 Global Organ-on-a-Chip Market Outlook, By Organ Type (2023-2034) ($MN)
  • Table 8 Global Organ-on-a-Chip Market Outlook, By Liver-on-Chip (2023-2034) ($MN)
  • Table 9 Global Organ-on-a-Chip Market Outlook, By Lung-on-Chip (2023-2034) ($MN)
  • Table 10 Global Organ-on-a-Chip Market Outlook, By Heart-on-Chip (2023-2034) ($MN)
  • Table 11 Global Organ-on-a-Chip Market Outlook, By Kidney-on-Chip (2023-2034) ($MN)
  • Table 12 Global Organ-on-a-Chip Market Outlook, By Gut-on-Chip (2023-2034) ($MN)
  • Table 13 Global Organ-on-a-Chip Market Outlook, By Brain-on-Chip (2023-2034) ($MN)
  • Table 14 Global Organ-on-a-Chip Market Outlook, By Skin-on-Chip (2023-2034) ($MN)
  • Table 15 Global Organ-on-a-Chip Market Outlook, By Blood Vessel-on-Chip (2023-2034) ($MN)
  • Table 16 Global Organ-on-a-Chip Market Outlook, By Bone Marrow-on-Chip (2023-2034) ($MN)
  • Table 17 Global Organ-on-a-Chip Market Outlook, By Pancreas-on-Chip (2023-2034) ($MN)
  • Table 18 Global Organ-on-a-Chip Market Outlook, By Placenta-on-Chip (2023-2034) ($MN)
  • Table 19 Global Organ-on-a-Chip Market Outlook, By Retina-on-Chip (2023-2034) ($MN)
  • Table 20 Global Organ-on-a-Chip Market Outlook, By Tumor-on-Chip (2023-2034) ($MN)
  • Table 21 Global Organ-on-a-Chip Market Outlook, By Lymph Node-on-Chip (2023-2034) ($MN)
  • Table 22 Global Organ-on-a-Chip Market Outlook, By Multi-Organ-on-Chip (2023-2034) ($MN)
  • Table 23 Global Organ-on-a-Chip Market Outlook, By Material (2023-2034) ($MN)
  • Table 24 Global Organ-on-a-Chip Market Outlook, By Polydimethylsiloxane (2023-2034) ($MN)
  • Table 25 Global Organ-on-a-Chip Market Outlook, By Thermoplastics (2023-2034) ($MN)
  • Table 26 Global Organ-on-a-Chip Market Outlook, By Glass (2023-2034) ($MN)
  • Table 27 Global Organ-on-a-Chip Market Outlook, By Silicon (2023-2034) ($MN)
  • Table 28 Global Organ-on-a-Chip Market Outlook, By Hydrogels (2023-2034) ($MN)
  • Table 29 Global Organ-on-a-Chip Market Outlook, By Extracellular Matrix-Based Materials (2023-2034) ($MN)
  • Table 30 Global Organ-on-a-Chip Market Outlook, By Hybrid Materials (2023-2034) ($MN)
  • Table 31 Global Organ-on-a-Chip Market Outlook, By Cell Source (2023-2034) ($MN)
  • Table 32 Global Organ-on-a-Chip Market Outlook, By Primary Cells (2023-2034) ($MN)
  • Table 33 Global Organ-on-a-Chip Market Outlook, By Induced Pluripotent Stem Cells (2023-2034) ($MN)
  • Table 34 Global Organ-on-a-Chip Market Outlook, By Embryonic Stem Cells (2023-2034) ($MN)
  • Table 35 Global Organ-on-a-Chip Market Outlook, By Immortalized Cell Lines (2023-2034) ($MN)
  • Table 36 Global Organ-on-a-Chip Market Outlook, By Patient-Derived Cells (2023-2034) ($MN)
  • Table 37 Global Organ-on-a-Chip Market Outlook, By Fabrication Method (2023-2034) ($MN)
  • Table 38 Global Organ-on-a-Chip Market Outlook, By Soft Lithography (2023-2034) ($MN)
  • Table 39 Global Organ-on-a-Chip Market Outlook, By Injection Molding (2023-2034) ($MN)
  • Table 40 Global Organ-on-a-Chip Market Outlook, By 3D Printing (2023-2034) ($MN)
  • Table 41 Global Organ-on-a-Chip Market Outlook, By Micro-Milling (2023-2034) ($MN)
  • Table 42 Global Organ-on-a-Chip Market Outlook, By Laser Micromachining (2023-2034) ($MN)
  • Table 43 Global Organ-on-a-Chip Market Outlook, By Hot Embossing (2023-2034) ($MN)
  • Table 44 Global Organ-on-a-Chip Market Outlook, By Throughput (2023-2034) ($MN)
  • Table 45 Global Organ-on-a-Chip Market Outlook, By Low-Throughput Platforms (2023-2034) ($MN)
  • Table 46 Global Organ-on-a-Chip Market Outlook, By Medium-Throughput Platforms (2023-2034) ($MN)
  • Table 47 Global Organ-on-a-Chip Market Outlook, By High-Throughput Platforms (2023-2034) ($MN)
  • Table 48 Global Organ-on-a-Chip Market Outlook, By Workflow Stage (2023-2034) ($MN)
  • Table 49 Global Organ-on-a-Chip Market Outlook, By Early Drug Discovery (2023-2034) ($MN)
  • Table 50 Global Organ-on-a-Chip Market Outlook, By Preclinical Research (2023-2034) ($MN)
  • Table 51 Global Organ-on-a-Chip Market Outlook, By Translational Research (2023-2034) ($MN)
  • Table 52 Global Organ-on-a-Chip Market Outlook, By Safety & Toxicology Assessment (2023-2034) ($MN)
  • Table 53 Global Organ-on-a-Chip Market Outlook, By Precision Medicine Research (2023-2034) ($MN)
  • Table 54 Global Organ-on-a-Chip Market Outlook, By Disease Area (2023-2034) ($MN)
  • Table 55 Global Organ-on-a-Chip Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 56 Global Organ-on-a-Chip Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 57 Global Organ-on-a-Chip Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 58 Global Organ-on-a-Chip Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
  • Table 59 Global Organ-on-a-Chip Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 60 Global Organ-on-a-Chip Market Outlook, By Gastrointestinal Disorders (2023-2034) ($MN)
  • Table 61 Global Organ-on-a-Chip Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 62 Global Organ-on-a-Chip Market Outlook, By Renal Diseases (2023-2034) ($MN)
  • Table 63 Global Organ-on-a-Chip Market Outlook, By Hepatic Diseases (2023-2034) ($MN)
  • Table 64 Global Organ-on-a-Chip Market Outlook, By Rare Diseases (2023-2034) ($MN)
  • Table 65 Global Organ-on-a-Chip Market Outlook, By Autoimmune Diseases (2023-2034) ($MN)
  • Table 66 Global Organ-on-a-Chip Market Outlook, By Technology (2023-2034) ($MN)
  • Table 67 Global Organ-on-a-Chip Market Outlook, By Microfluidics (2023-2034) ($MN)
  • Table 68 Global Organ-on-a-Chip Market Outlook, By 3D Cell Culture (2023-2034) ($MN)
  • Table 69 Global Organ-on-a-Chip Market Outlook, By Tissue Engineering (2023-2034) ($MN)
  • Table 70 Global Organ-on-a-Chip Market Outlook, By 3D Bioprinting (2023-2034) ($MN)
  • Table 71 Global Organ-on-a-Chip Market Outlook, By Stem Cell Technology (2023-2034) ($MN)
  • Table 72 Global Organ-on-a-Chip Market Outlook, By Biosensor Integration (2023-2034) ($MN)
  • Table 73 Global Organ-on-a-Chip Market Outlook, By Organoid-on-Chip (2023-2034) ($MN)
  • Table 74 Global Organ-on-a-Chip Market Outlook, By Application (2023-2034) ($MN)
  • Table 75 Global Organ-on-a-Chip Market Outlook, By Drug Discovery (2023-2034) ($MN)
  • Table 76 Global Organ-on-a-Chip Market Outlook, By Drug Screening (2023-2034) ($MN)
  • Table 77 Global Organ-on-a-Chip Market Outlook, By Toxicity Testing (2023-2034) ($MN)
  • Table 78 Global Organ-on-a-Chip Market Outlook, By Disease Modeling (2023-2034) ($MN)
  • Table 79 Global Organ-on-a-Chip Market Outlook, By Personalized Medicine (2023-2034) ($MN)
  • Table 80 Global Organ-on-a-Chip Market Outlook, By ADME Studies (2023-2034) ($MN)
  • Table 81 Global Organ-on-a-Chip Market Outlook, By Pharmacokinetic (PK) Studies (2023-2034) ($MN)
  • Table 82 Global Organ-on-a-Chip Market Outlook, By Pharmacodynamic (PD) Studies (2023-2034) ($MN)
  • Table 83 Global Organ-on-a-Chip Market Outlook, By Cancer Research (2023-2034) ($MN)
  • Table 84 Global Organ-on-a-Chip Market Outlook, By Regenerative Medicine Research (2023-2034) ($MN)
  • Table 85 Global Organ-on-a-Chip Market Outlook, By Infectious Disease Research (2023-2034) ($MN)
  • Table 86 Global Organ-on-a-Chip Market Outlook, By Neuroscience Research (2023-2034) ($MN)
  • Table 87 Global Organ-on-a-Chip Market Outlook, By Cosmetic Testing (2023-2034) ($MN)
  • Table 88 Global Organ-on-a-Chip Market Outlook, By End User (2023-2034) ($MN)
  • Table 89 Global Organ-on-a-Chip Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 90 Global Organ-on-a-Chip Market Outlook, By Biotechnology Companies (2023-2034) ($MN)
  • Table 91 Global Organ-on-a-Chip Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 92 Global Organ-on-a-Chip Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 93 Global Organ-on-a-Chip Market Outlook, By Hospitals & Clinical Research Centers (2023-2034) ($MN)
  • Table 94 Global Organ-on-a-Chip Market Outlook, By Regulatory Agencies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.